secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2026-07-13T12:30:43+00:00
Accession:  0001104659-26-082897
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen signs binding term sheet with Roots Pharmaceutical to license OCU400 in MENA; up to $255M milestones, 22% royalty
--------------------------------------------------------------------------------

- Upfront and near-term development milestones up to $4M; sales milestones up to $255M.
- Ocugen to receive 22% royalty on net sales of OCU400 in MENA region.
- Definitive license agreement expected within 90 days; Ocugen to manufacture supply.
- OCU400 is a modifier gene therapy for retinitis pigmentosa, a leading cause of inherited vision loss.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000110465926082897/0001104659-26-082897-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000110465926082897/tm2620295d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-082897

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer